Literature DB >> 33015815

Italian SARS-CoV-2 patients in intensive care: towards an identikit for subjects at risk?

M Baronio1, A Freni-Sterrantino, M Pinelli, G Natalini, G Tonini, M Marri, M Baglivo, T Sabatini, P E Maltese, P Chiurazzi, S Michelini, G Morreale, A Ascione, P Notaro, M Bertelli.   

Abstract

OBJECTIVE: To investigate patient characteristics and factors that increase the risk of being admitted to intensive care and that influence survival in cases of SARS-CoV-2 pneumonia. PATIENTS AND METHODS: One-hundred and ninety-one SARS-CoV-2 patients were admitted to the "Fondazione Poliambulanza di Brescia" Hospital (Brescia, Lombardy, Italy) in the period 1st March 2020 to 11th April 2020. Data on demographics, clinical presentation at admission, co-morbidities, pharmacological treatment, admission to intensive care and death was recorded. Logistic regression and survival analysis were carried out to investigate the risk of being admitted to intensive care and the risk of death.
RESULTS: The mean age of the study cohort was 64.6±9.9 years (range 20-88). Median BMI was 28.5±5 kg/m2. Fever (81%) and dyspnea (65%) were the most common symptoms on admission. Most of patients (63%) had at least one co-existing disease. The 157 (82%) patients admitted to intensive care were more likely to be of intermediate age (60-69 years; OR 3.23, 95% CI 1.32-8.38), overweight (OR 2.66, 95% CI 1.02-7.07) or obese (OR 5.63, 95% CI 1.73-21.09) and with lymphocytopenia (OR 2.75, 95% CI 1.17-6.89) than the 34 patients admitted to the ordinary ward. During intensive care, 50% of patients died and their death was associated with older age (HR 2.06, 95% CI 1.07-3.97), obesity (HR 2.23, 95% CI 1.15-4.35) and male gender (HR 1.9, 95% CI 1.02-3.57).
CONCLUSIONS: We found that admission to intensive care and poor survival were associated with advanced age and higher body mass index, albeit with differences in statistical significance. Pre-existing diseases and symptoms on admission were not associated with different clinical outcomes. Interestingly, male gender was more prevalent among SARS-CoV-2 patients and was related negatively to survival, but it was not associated with more frequent admission to intensive care.

Entities:  

Mesh:

Year:  2020        PMID: 33015815     DOI: 10.26355/eurrev_202009_23061

Source DB:  PubMed          Journal:  Eur Rev Med Pharmacol Sci        ISSN: 1128-3602            Impact factor:   3.507


  5 in total

1.  An Italian individual-level data study investigating on the association between air pollution exposure and Covid-19 severity in primary-care setting.

Authors:  Valeria Pegoraro; Franca Heiman; Antonella Levante; Duccio Urbinati; Ilaria Peduto
Journal:  BMC Public Health       Date:  2021-05-12       Impact factor: 3.295

Review 2.  Genomic variation, origin tracing, and vaccine development of SARS-CoV-2: A systematic review.

Authors:  Tianbao Li; Tao Huang; Cheng Guo; Ailan Wang; Xiaoli Shi; Xiaofei Mo; Qingqing Lu; Jing Sun; Tingting Hui; Geng Tian; Leyi Wang; Jialiang Yang
Journal:  Innovation (Camb)       Date:  2021-05-11

3.  Development and validation of the CoV19-OM intensive care unit score: An early ICU identification for laboratory-confirmed SARS-CoV-2 patients from a retrospective cohort study in Oman.

Authors:  Eduardo M Lacap; Abraham Varghese; Faryal Khamis; Maher Al Bahrani; Hamed Al Naamani; Shajidmon Kolamban; Samata Al Dowaiki; Huda Salim Al Shuaily
Journal:  Int J Infect Dis       Date:  2021-04-24       Impact factor: 12.074

Review 4.  The 15-Months Clinical Experience of SARS-CoV-2: A Literature Review of Therapies and Adjuvants.

Authors:  Alessio Danilo Inchingolo; Gianna Dipalma; Angelo Michele Inchingolo; Giuseppina Malcangi; Luigi Santacroce; Maria Teresa D'Oria; Ciro Gargiulo Isacco; Ioana Roxana Bordea; Sebastian Candrea; Antonio Scarano; Benedetta Morandi; Massimo Del Fabbro; Marco Farronato; Gianluca Martino Tartaglia; Mario Giosuè Balzanelli; Andrea Ballini; Ludovica Nucci; Felice Lorusso; Silvio Taschieri; Francesco Inchingolo
Journal:  Antioxidants (Basel)       Date:  2021-05-31

Review 5.  SARS-CoV-2 Disease Adjuvant Therapies and Supplements Breakthrough for the Infection Prevention.

Authors:  Alessio Danilo Inchingolo; Angelo Michele Inchingolo; Ioana Roxana Bordea; Giuseppina Malcangi; Edit Xhajanka; Antonio Scarano; Felice Lorusso; Marco Farronato; Gianluca Martino Tartaglia; Ciro Gargiulo Isacco; Grazia Marinelli; Maria Teresa D'Oria; Denisa Hazballa; Luigi Santacroce; Andrea Ballini; Maria Contaldo; Francesco Inchingolo; Gianna Dipalma
Journal:  Microorganisms       Date:  2021-03-04
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.